Becton, Dickinson and Company (NYSE:BDX) Stock Bumped Up to “Strong-Buy” by Zacks Research

Posted by Stanley Muller on Oct 23rd, 2026

Zacks Research upgraded shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) from a hold rating to a strong-buy rating in a research report report published on Wednesday morning,Zacks reports.

A number of other analysts have also issued reports on BDX. Jefferies Financial Group reiterated a “buy” rating and set a $210.00 price objective on shares of Becton, Dickinson and Company in a research note on Thursday, August 6th. Bank of America raised their target price on Becton, Dickinson and Company from $185.00 to $200.00 and gave the stock a “neutral” rating in a research note on Monday, August 31st. Citigroup reaffirmed a “buy” rating on shares of Becton, Dickinson and Company in a report on Thursday, August 13th. Weiss Ratings upgraded Becton, Dickinson and Company from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, September 28th. Finally, Wolfe Research initiated coverage on shares of Becton, Dickinson and Company in a report on Tuesday. They issued an “outperform” rating on the stock. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $185.07.

Get Our Latest Stock Analysis on BDX

Becton, Dickinson and Company Stock Up 3.0%

Becton, Dickinson and Company stock opened at $200.21 on Wednesday. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $200.47. The firm has a market capitalization of $55.16 billion, a price-to-earnings ratio of 60.30, a P/E/G ratio of 13.10 and a beta of 0.21. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55. The firm has a 50 day simple moving average of $185.10 and a 200 day simple moving average of $164.86.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last issued its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.14 by $0.09. The business had revenue of $4.98 billion for the quarter, compared to analysts’ expectations of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The business’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, analysts predict that Becton, Dickinson and Company will post 12.67 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th were given a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.1%. The ex-dividend date was Wednesday, September 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 126.51%.

Insider Buying and Selling

In related news, CEO Thomas Polen, Jr. sold 4,152 shares of Becton, Dickinson and Company stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $185.00, for a total transaction of $768,120.00. Following the completion of the sale, the chief executive officer owned 110,163 shares of the company’s stock, valued at approximately $20,380,155. This trade represents a 3.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Feld sold 165 shares of the business’s stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total value of $31,100.85. Following the transaction, the executive vice president owned 19,720 shares of the company’s stock, valued at approximately $3,717,022.80. The trade was a 0.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 6,906 shares of company stock worth $1,265,855. Corporate insiders own 0.40% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Maryland Capital Advisors Inc. raised its stake in Becton, Dickinson and Company by 13,900.0% in the third quarter. Maryland Capital Advisors Inc. now owns 140 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 139 shares in the last quarter. Meeder Asset Management Inc. lifted its position in Becton, Dickinson and Company by 152.2% during the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock valued at $27,000 after purchasing an additional 102 shares during the last quarter. Main Street Group LTD purchased a new position in Becton, Dickinson and Company in the 1st quarter worth approximately $29,000. Bell Investment Advisors Inc purchased a new position in Becton, Dickinson and Company in the 2nd quarter worth approximately $29,000. Finally, Kelleher Financial Advisors purchased a new position in Becton, Dickinson and Company in the 2nd quarter worth approximately $30,000. 86.97% of the stock is currently owned by institutional investors.

About Becton, Dickinson and Company

(Get Free Report)

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD’s products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.